JNJ NYSE

Johnson & Johnson

Health Care ·Pharmaceuticals & medical technology ·Common Stock
Dividend per share · FY2025$5.14as reported in the 10-K
Latest quarterly dividend$1.34quarter ended 2026-09-27 · filing
Dividend growth · 5 years5.2%compound annual rate
FCF cover · FY20251.59x3-year average 1.61x
Consecutive increases4years, within FY2021–FY2025

JNJ dividend record

Annual figures as reported in Johnson & Johnson’s Form 10-K filings with the US SEC. Free cash flow = operating cash flow − capital expenditure. FCF cover = free cash flow ÷ dividends paid. Each row links to its filing. Data as of SEC EDGAR, retrieved 14 Nov 2026.

Fiscal yearYear endDividend / shareChangeDividends paidFree cash flowFCF coverSource
FY20252025-12$5.14+4.7%$12.38bn$19.70bn1.59x10-K data
FY20242024-12$4.91+4.5%$11.82bn$19.84bn1.68x10-K data
FY20232023-12$4.70+5.6%$11.77bn$18.25bn1.55x10-K data
FY20222023-01$4.45+6.2%$11.68bn$17.18bn1.47x10-K data
FY20212022-01$4.19+5.3%$11.03bn$19.76bn1.79x10-K data
FY20202021-01$3.98+6.1%$10.48bn$20.19bn1.93x10-K data
FY20192019-12$3.75+5.9%$9.92bn$19.92bn2.01x10-K data
FY20182018-12$3.54+6.6%$9.49bn$18.53bn1.95x10-K data
FY20172017-12$3.32+5.4%$8.94bn$17.78bn1.99x10-K data
FY20162017-01$3.15—$8.62bn$15.54bn1.80x10-K data
  • Dividend per share rose every year in the 10-year window shown (FY2016–FY2025). Records before FY2016 are not yet verified on DIVpedia, so we do not state a longer streak.
  • Johnson & Johnson uses a 52/53-week fiscal year, so some fiscal years end in early January of the following calendar year. We label each year by the calendar year it mostly covers.
  • Dividend per share here is the amount paid in each fiscal year, as the company reports it.

Original source: Johnson & Johnson filings on SEC EDGAR · How we calculate · Report an error

General information only — not financial advice. Share prices and dividend yields are not shown until a licensed price feed is connected.

About Johnson & Johnson

Johnson & Johnson develops prescription medicines and medical devices. It separated its consumer-health business into Kenvue in 2023.

Common Stock 1.5-2x Quarterly